Novartis (AG) v Ivax Pharmaceuticals UK Ltd
Equoral does not infringe the patent because the majority of the active ingredient is not carried by microemulsion-sized particles, which is the core teaching and purpose of the patent. Additionally, Equoral does not contain a lipophilic phase as required by the claim, as its candidate component is amphiphilic and does not meet the patent's requirements.
- Parties
- Claimant/appellant: Novartis AG; Defendant/respondent: IVAX Pharmaceuticals UK Limited
- Jurisdiction
- England and Wales
- Judgment Date
- 18 October 2007
- Procedural Posture
- Civil Appeal (patent Infringement) / Appeal From High Court (patents Court)
- Outcome
- Appeal dismissed
- Legal Topics
- Patent Infringement, Claim Construction, Pharmaceutical Patents
Case Brief
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
Novartis AG
Claimant/appellant
IVAX Pharmaceuticals UK Limited
Defendant/respondent
Procedural Posture
Civil Appeal (patent Infringement) / Appeal From High Court (patents Court)
Legal Issues
- 1 Whether IVAX's Equoral product infringes Novartis's UK patent No. 2,222,770
- 2 Proper construction of 'oil-in-water microemulsion pre-concentrate' in the patent claim
- 3 Whether Equoral contains a 'lipophilic phase' as required by the claim
Ratio Decidendi
Equoral does not infringe the patent because the majority of the active ingredient is not carried by microemulsion-sized particles, which is the core teaching and purpose of the patent. Additionally, Equoral does not contain a lipophilic phase as required by the claim, as its candidate component is amphiphilic and does not meet the patent's requirements.
Court Disposition
Appeal dismissed
Orders
- Appeal dismissed; High Court decision of non-infringement affirmed
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment